TERMINATION OF PREGNANCY AFTER INTRA AND EXTRA AMNIOTIC INSTILLATION OF PROSTAGLANDIN

BY NEELA SHARMA and

KAMLA ACHARI

SUMMARY

Sixty-two cases of medical termination of pregnancy of 10-12 weeks duration with prostanglandin PGF2 and its analogue 15(s) 15 methyl PGF2 α are presented. The termination was done both by extra and intra-amniotic route.

In 37 cases 15(s) 15 methyl PGF2 α 1 Mg. was used as single injection with success rate of about 75%. In the remaining 25 cases prostaglandins used were 15(s) 15 methyl PGF2 α (2.5 mg 14 cases) and PGF2 α (50 mg 11 cases). Prostaglandin was used by single injection by intra-amniotic route with success rate of 86%. The technique is simple, the injection abortion interval short, and side effects are mainly in the form of diarrhoea and vomiting.

Introduction

Prostaglandins have important clinical applications in obstetrics and gynaecology, particularly for the induction of labour and as the method of choice for inducing second trimester abortion. In the sphere of reproduction the best known and most widely studied prostaglandins are prostaglandin E_2 (PGE2) and prostaglandin $F_{2\alpha}$.

The exact mechanism of prostaglandin induced abortion is still uncertain. But Csapo's (1974) multistep hypothesis is generally accepted, despite sporadic conflicting results. According to this hypo-

thesis, the evolution of uterine activity following prostaglandin administration results from the lowering sequence of events, direct prostaglandin impact causing myometrial contracture, reduction in uterine blood flow and depression of placental endocrine function, drop in estrogen and progesterone levels, lowering of myometrial reactivity threshold to endogenous and increased PGF2a PGFα synthesis-self sustaining evolution of uterine activity and reactivity ending in clinical abortion.

Material and Methods

Sixty-two patients were selected for study, from the women in the age group of 16-44 with pregnancy between 10-20 weeks duration admitted in the obstetrics

From: Dept. of Obstetrics and Gynaecology, Patna Medical College Hospital, Patna and B.R.D. Medical College, Gorakhpur.

Accepted for publication on 9-10-84.

and gynaecology department, Patna Medical College Hospital Patna.

As prostaglandin is contraindicated in conditions like heart disease, respiratory disease, kidney disease and diabetes mellitus the patients suffering from these diseases were excluded from the series.

Prostaglandins were used by two methods by single dose only.

Extra-amniotic: Total cases done by this method were 37, Prostaglandin used was 15(s) methyl PGF $\alpha = 1$ mg contained in 2 ml. ampoule.

Intra-amniotic method: Twenty-five were done by intra-amniotic route. Out of 25, in 14 cases prostaglandin used was 15 (s) 15 methyl PGF2 $\alpha = 2.5$ mg. (i.e. 2.5 amp.) in the remaining 11 cases prostaglandin F2 α (50 mg.) contained in 10 C.C. ampoule was used.

The trial was considered as a failure if abortion did not take place within 48 hours with intra-amniotic or within 36 hours with extra-amniotic route. Expulsion of only foetus or placenta made it incomplete abortion. Failed cases were treated by oxytocin drip, hysterotomy or suction evacuation depending upon the period of gestation.

Observation

Table I: Shows that out of 62 cases, in 25 cases (15-20 weeks duration) termination was done by intra-amniotic route. Out of which 11 cases were terminated Out of these 25 cases, 11 were terminated by $PGF2\alpha$ (50 mg.) and 14 by 15(s) 15 methyl $PGF2\alpha$ = (2.5 mg.). In the remaining 37 cases (10-20 weeks) termination was done by 15(s) 15 methyl $PGF2\alpha$ (1 mg.) by extra-amniotic route.

Table II: Shows that side effects in intra-amniotic series were in the form of diarrhoea and vomiting. In 44% complaints were of diarrhoea and vomiting both, while diarrhoea only occurred in 16% of the cases; vomiting in 12%. 12%

TABLE I
Mode of Induction

Total No. of cases		e prostaglandin weeks)	Extra amniotic prostaglandin	(10-20 weeks)	
	PGF 2α (50 mg)	15(s) 15 methyl PGF2 α(2.5 mg)	15(s) 15 methyl	(PGF 2α (1 mg.)	
62	11	14	37		

TABLE II
Side Effects

Side	Intra-amni	otic series	Extra-amniotic series			
effecs	No. of cases	Percentage	No. of caes	Percentage		
Diarrhoea	4	16	12	32		
Vomiting	3	12	3	8		
Fever	1	4	Nil	0		
Headache	1	4	Nil	0		
Chest pain	1	4	Nil	0		
Dyspnoea	Nil	0	2	5		
Diarrhoea &						
vomiting	11	44	10	27		

of the cases complained of fever, headache, chest pain, dysphoea. Similarly, in extra-amniotic series side effects were mainly diarrhoea and vomiting. Diarrhoea vomiting together occurred in 27%, only diarrhoea in 32% and vomiting in 8%. Only 5% had dysphoea.

Table III: Shows that average induction abortion interval was the same i.e. 15 hours in both routes. But the success rate with 15(s) 15 methyl PGF2 α was 93% and with PGF2 α 73% when used extra-amniotically. Success rate was 75% with 15(s) 15 methyl PGF2 α when used intra-amniotically.

TABLE III
Induction—Abortion Intervel

Induction abortion interval (in hrs.)		Inra- Amniotic 7-23 (15)
Success rate %	73 PGF2 98% 15(s) 15 Methyl PGF2	75

Table IV: In txtra-amniotic series, 14% had complete abortion and 86% had incomplete abortion. Out of 8 failure cases, 5 were treated by suction evacua-

tion and rest by hysterotomy. In intraamniotic group, 86% had complete and 14% had incomplete abortion. Out of 4 failure cases of intra-amniotic, 3 were treated by hysterotomy and 1 by oxytocin infusion.

Discussion

Brener et al (1972) studied the effect of single dose of PGF2α by intra-amniotic route in 40 women, 13-26 weeks pregnant, requiring termination of pregnancy. Twenty-five patients received 10 mg. prochlorperazine intramuscularly to alleviate nausea or vomiting when they requested. Fifteen subjects were given 10 mg. prochlorperazine 30 minutes before PGF2a and at 6 hours interval until abortion. 77% of patients aborted within 22 hours and 95% within 48 hours. Thus, the results are quite similar to our series. Mean induction abortion interval was 19.1 hours which was more than that in the present series. In Brener's series, 68% had complete abortion, 28% incomplete abortion and 5% failed to abort within 48 hours. Therefore, we see that the present series

TABLE IV

Route of	Successful cases					Failed	cases			
	Complete abortion			incomplete abortion				Treated by		
Admini- stration	No.	%	No.	%	Treated by Eva- cuation	No.	%	Suction evacuation	Hystero- tomy	Oxytocin drip
Extra- amniotic	4	14	25	86	Instrumental Evacuation	8	25	5	3	2 (Failed in both)
Intra- amniotic	18	86	3	14	-do-	4	16	Nil	3	(Success- ful in one)

shows higher incidence of complete abortion i.e. 86%. The side effects like nausea and vomiting were less in Brener's (1972) series.

Csapo (1974) utilized very high extraamniotic dose of PGF2 α (5-10 mg.) to induce abortion. However, the patient has to be premedicated with analgesics and sedatives to reduce the side effects provoked by the massive PGF2 α therapy.

Hingorani (1974) studied the effect of PGF2 α in 43 cases. She used the drug in divided doses. The initial does was 25 mg. And after 6 hours second dose was given by an indwelling catheter. Abortion occurred in 86% of the cases within 48 hours with mean induction abortion interval of 20 hours. In this series 15 (s) 15 methyl PGF2 α was given by single injection with success rate of 75% and mean induction abortion interval of 15 hours.

Bygdeman et al (1975) by a clinical study of cases between 13-16 weeks duration by single injection of 15 methyl PGF2α (730 micro gram) showed success in more than 80% of the cases. Injection-abortion interval was 13.6 hours. There was an average 1.5 episodes of vomiting and diarrhoea per abortion trial in both sides. The results of Bygdeman is very close to those of the series.

The clinical results using the same abortion method differ considerably due to variations in technical performance of the procedure. A comparison of two different abortion methods require therefore that a randomised study is conducted in the same institution by the same personnel.

References

- Brenner, W. E., Hendrick, G. H., Braaksma, J. T., Fishburne, J. I. Jr., Kroncke, F. G. Jr. and staurovsky, L.: J. Obstet. Gynaec. 114: 787, 1972.
- Bygdeman, M., Topozada, M. and Wiquist N.: Gynecologic Endocrinology, 2nd ed. 1975, P. 595, Editor Gold G.
- Csapo, A. I.: Population Report, series G., No. 4, March, 1974.
- 4. Hingarani, V.: Contraception, 10: 13,